Handel nachbörslich: 10.78

Lexeo Therapeutics Inc (LXEO)

Lexeo Therapeutics Inc Aktie (LXEO) Neueste Nachrichten

Lexeo Therapeutics Inc (LXEO)

Lexeo Therapeutics Inc Aktie (LXEO) Neueste Nachrichten

Can you now get a good deal on Lexicon Pharmaceuticals Inc’s shares? - US Post News

Aurobindo to acquire 49% stake in GLS Pharma for Rs 22.5 crore - The Economic Times

LXP Industrial Trust (NYSE:LXP) PT Raised to $11.00 at Evercore ISI - Defense World

Lexicon Pharmaceuticals President and COO Jeffrey Wade to step down - The Business Journals

How Analyst Ratings Affect Leap Therapeutics Inc Inc. (LPTX) Price Performance - The InvestChronicle

Quest Partners LLC Acquires 11,597 Shares of LXP Industrial Trust (NYSE:LXP) - Defense World

Financial Analysis: Lexaria Bioscience (NASDAQ:LEXX) & Xeris Biopharma (NASDAQ:XERS) - Defense World

Get in on Lexicon Pharmaceuticals Inc’s (LXRX) buy-in window today! - SETE News

LXP Industrial Trust price target raised to $11 from $10 at Evercore ISI - TipRanks

Investor’s Delight: Lexicon Pharmaceuticals Inc (LXRX) Closes Strong at 1.70, Up 1.80 - The Dwinnex

Objective long/short (LXEO) Report - Stock Traders Daily

Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Receives $22.14 Consensus Price Target from Analysts - MarketBeat

Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Short Interest Update - MarketBeat

Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Given Average Recommendation of “Buy” by Analysts - Defense World

Gene Therapies For Cardiomyopathies Market Growth Anticipated - openPR

The Globe and Mail - The Globe and Mail

Lexeo Therapeutics, Inc. (NASDAQ:LXEO) CEO Richard Nolan Townsend Sells 5,000 Shares - MarketBeat

Lexeo Therapeutics to Participate in Upcoming Investor Conferences - GlobeNewswire

Lexeo Therapeutics to Participate in Upcoming Investor Conferences - StockTitan

Top investors say Lexeo Therapeutics Inc. (LXEO) ticks everything they need - SETE News

The Lexeo Therapeutics Inc. (LXEO) had a good session last reading, didn’t it? - US Post News

Short Interest in Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Expands By 16.9% - MarketBeat

Trading (LXEO) With Integrated Risk Controls - Stock Traders Daily

Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Receives $22.14 Average Price Target from Analysts - MarketBeat

Chardan Capital Comments on Lexeo Therapeutics, Inc.'s FY2024 Earnings (NASDAQ:LXEO) - MarketBeat

Vanguard Group Inc. Grows Position in Lexeo Therapeutics, Inc. (NASDAQ:LXEO) - MarketBeat

Stifel maintains 'Buy' on Lexeo stock, confident amid trial progress By Investing.com - Investing.com Canada

Chardan Capital Weighs in on Lexeo Therapeutics, Inc.'s FY2025 Earnings (NASDAQ:LXEO) - MarketBeat

Lexeo Therapeutics (NASDAQ:LXEO) Stock Rating Reaffirmed by Chardan Capital - Defense World

Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Expected to Earn Q3 2024 Earnings of ($0.64) Per Share - MarketBeat

Q3 2024 Earnings Estimate for Lexeo Therapeutics, Inc. Issued By Leerink Partnrs (NASDAQ:LXEO) - Defense World

Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Expected to Earn Q3 2024 Earnings of ($0.64) Per Share - Defense World

Royal Bank of Canada Reiterates Outperform Rating for Lexeo Therapeutics (NASDAQ:LXEO) - Defense World

Lexeo Therapeutics (NASDAQ:LXEO) Posts Quarterly Earnings Results, Hits Estimates - MarketBeat

Lexeo Therapeutics CEO sells $57.6k in company stock By Investing.com - Investing.com Australia

Lexeo Therapeutics (NASDAQ:LXEO) Given "Buy" Rating at Chardan Capital - MarketBeat

Lexeo Therapeutics (NASDAQ:LXEO) Price Target Lowered to $21.00 at HC Wainwright - Defense World

Lexeo Therapeutics, Inc. (NASDAQ:LXEO) CEO Richard Nolan Townsend Sells 5,000 Shares of Stock - Defense World

Lexeo Therapeutics CEO sells $57.6k in company stock - Investing.com

Lexeo Therapeutics (NASDAQ:LXEO) Given New $21.00 Price Target at HC Wainwright - MarketBeat

Lexeo Therapeutics (NASDAQ:LXEO) Given "Outperform" Rating at Royal Bank of Canada - MarketBeat

Comparing Cognition Therapeutics (NASDAQ:CGTX) & Lexeo Therapeutics (NASDAQ:LXEO) - Defense World

LXEO Stock Earnings: Lexeo Therapeutics Beats EPS for Q2 2024 - InvestorPlace

LXEO Stock Earnings: Lexeo Therapeutics Beats EPS for Q2 2024 - MSN

Lexeo Therapeutics Reports Second Quarter 2024 Financial Results and Operational Highlights - GlobeNewswire

Lexeo Therapeutics Reports Second Quarter 2024 Financial Results and Operational Highlights - StockTitan

Lexeo Therapeutics Inc.’s latest rating changes from various analysts - Knox Daily

American International Group Inc. Invests $79,000 in Lexeo Therapeutics, Inc. (NASDAQ:LXEO) - Defense World

Contrasting Lexeo Therapeutics (NASDAQ:LXEO) & Kiromic BioPharma (NASDAQ:KRBP) - Defense World

Janus Henderson Group PLC Acquires 210,047 Shares of Lexeo Therapeutics, Inc. (NASDAQ:LXEO) - MarketBeat

Robert W. Baird gives an Outperform recommendation for Lexeo Therapeutics Inc. (LXEO) - Knox Daily

BNP Paribas Financial Markets Takes Position in Lexeo Therapeutics, Inc. (NASDAQ:LXEO) - Defense World

Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Given Consensus Recommendation of "Buy" by Brokerages - MarketBeat

Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Given Consensus Recommendation of “Buy” by Brokerages - Defense World

LXEO (Lexeo Therapeutics Inc.) may reap gains as insiders became active recently - Knox Daily

Lexeo Therapeutics Inc. (LXEO) deserves closer scrutiny - US Post News

Lexeo Therapeutics, Inc. to Post Q3 2024 Earnings of ($0.59) Per Share, Leerink Partnrs Forecasts (NASDAQ:LXEO) - Defense World

Q3 2024 EPS Estimates for Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Decreased by Analyst - MarketBeat

Biotech Stock Roundup: LXRX Up on Regulatory Update, SAVA, LXEO Down on Updates - Yahoo Finance

Lexeo Down Despite Upbeat Rare Disease Gene Therapy Data - Markets Insider

Friedreich's Ataxia Market to Grow at a Substantial Growth Rate by 2034, Examines DelveInsight | Key CompaniesRetrotope, PTC Therapeutics, Minoryx Therapeutics, Biogen, Lexeo Therapeutics, Larimar Therapeutics - India Shorts

Lexeo: Higher Dosing LX2006 Could Ignite FA Cardiomyopathy Program Further (NASDAQ:LXEO) - Seeking Alpha

Friedreich's Ataxia Market to Grow at a Substantial Growth - GlobeNewswire

Ähnlich wie LXEO